SCHEMBL1381986

SCHEMBL1381986

CCOC(=O)c1sc2ccccc2c1OCCOc1ccccc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.69
LMNA P02545 4/20 0.69
GAA P10253 4/20 0.69
NPSR1 Q6W5P4 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
ALDH1A1 P00352 6/20 0.59
KMT2A Q03164 5/20 0.59
NOD2 Q9HC29 1/20 0.57
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRB1 P18505 1/20 0.47
GABRG2 P18507 1/20 0.47
GABRB3 P28472 1/20 0.47
GABRA5 P31644 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
GABRA4 P48169 1/20 0.47
GABRE P78334 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634058 0.88 MAPT (0.59) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633535 0.86 MAPT (0.57) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633849 0.85 CXCR2 (0.52) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633857 0.84 KMT2A (0.66) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633609 0.84 LMNA (0.54) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633973 0.83 MAPT (0.74) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4634446 0.83 ALDH1A1 (0.58) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4605365 0.82 LMNA (0.56) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4635075 0.81 KMT2A (0.65) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633845 0.81 KMT2A (0.65) MAPTLMNAGAANPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4786545-B2 2011-10-05 JP claimed
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP claimed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US claimed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US claimed
EP-1685121-A1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES MERCK PATENT GmbH (DE) 2006-08-02 EP claimed
WO-2005054225-A1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2005-06-16 WO claimed
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives GPR119, INSR, GLP1R MAPT 2481/4885LMNA 3220/4885GAA 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.